Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer
Baseline and on-treatment ctDNA dynamics may provide an early indication of benefit from letrozole/abemaciclib in EC. ctDNA at the time of progression may identify resistance alterations that may inform subsequent therapy.
Authors
- Oladapo Yeku (ORCID: https://orcid.org/0000-0002-6319-1647)
- Elizabeth K. Lee (ORCID: https://orcid.org/0000-0001-7533-7853)
- Meghan Shea (ORCID: https://orcid.org/0000-0001-5262-1245)
- Mingyang Cai (ORCID: https://orcid.org/0000-0001-8063-1002)
- Hannah Sawyer
- Martin Hayes (ORCID: https://orcid.org/0000-0001-8998-9713)
- Madeline Polak (ORCID: https://orcid.org/0000-0002-1331-3845)
- Carolyn Krasner
- Alexi A. Wright (ORCID: https://orcid.org/0000-0002-9776-7114)
- Susana M. Campos (ORCID: https://orcid.org/0000-0001-9672-473X)
- Ursula A. Matulonis (ORCID: https://orcid.org/0000-0002-3103-6992)
- Joyce F. Liu (ORCID: https://orcid.org/0000-0003-3888-3972)
- Cesar M. Castro (ORCID: https://orcid.org/0000-0002-1159-5658)
- Caroline Weipert (ORCID: https://orcid.org/0000-0002-0069-882X)
- Panagiotis A. Konstantinopoulos (ORCID: https://orcid.org/0000-0002-1032-1479)
- Sara Bouberhan (ORCID: https://orcid.org/0000-0002-0315-2152)
- Heather A. Parsons (ORCID: https://orcid.org/0000-0001-8178-6612)
- Neil S. Horowitz (ORCID: https://orcid.org/0000-0002-4854-0642)
- Richard T. Penson (ORCID: https://orcid.org/0000-0002-8091-8588)
- Su–Chun Cheng
Institutions
- Beth Israel Deaconess Medical Center (US)
- Massachusetts General Hospital (US)
- Guardant (United States) (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1200/po-24-00882
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.81